相关实验视频

Updated: Sep 11, 2025

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

系统生物学支持的NF-κΒ和BCL2的向克服了DLBCL中微环境介导的BH3-模拟性抵抗

Aimilia Vareli¹, Haripriya Vaidehi Narayanan², Heather Clark¹

¹Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, University of Brighton and University of Sussex, Brighton, BN1 9PX, UK.

Cell death & disease

|August 16, 2025

概括

由于蛋白质异质性,扩散性大B细胞淋巴瘤 (DLBCL) 的向治疗是复杂的. 结合分子分析和计算建模,发现了BCL2和NF-κB抑制的漏洞,克服了抵抗机制.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
计算生物学计算生物学

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 的特征是抗亡性BCL2家族蛋白和NF-κB子单元的升高,与预后不佳相关.
治疗策略因异质蛋白表达,复杂调节和冗余而复杂,阻碍了有效的向治疗.
识别特定的漏洞对于开发有效的DLBCL治疗方法至关重要.

研究的目的:

通过整合流细胞计,免疫光成像和计算建模来确定DLBCL的治疗漏洞.
预测对BCL2和非正规NF-κB抑制的选择性反应.
了解和克服DLBCL中针对性治疗的耐药性机制.

主要方法:

利用流式细胞计"指纹"和免疫光成像来分析蛋白质表达和细胞异质性.
采用计算建模来预测治疗反应和识别抵抗机制.
在模仿瘤微环境 (TME) 的共同培养模型中研究了耐药性,并通过实验验验证了计算预测.

主要成果:

对BCL2抑制 (venetoclax) 和非正规NF-κB抑制 (Amgen16) 的预测选择性反应.
在DLBCL亚群中确定了独特的BCL2抑制抵抗机制,并证明了TME诱导的对BH3-模拟剂的抵抗.
表明基底NF-κB激活决定了抵抗路径,可以通过BTK抑制或非正规NF-κB抑制克服.

结论:

结合分子指纹和计算建模,为DLBCL的精密治疗提供了一种策略.
非正规NF-κB抑制可以克服异质的补偿BCL2上调,恢复对BH3-模拟剂的敏感性.
针对BCL2家族蛋白和NF-κB通路,有望克服DLBCL中的抗性.

更多相关视频

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

Enhancing Tumor Content through Tumor Macrodissection

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

相关概念视频

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...